Skip to content
value.today
ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH
$87 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$4 M
For year ending December-2025
Net income
$-15 M
-339.6% margin
SEC filing
Employees
19
As of December 31, 2025
SEC filing

ProPhase Labs, Inc. in brief

ProPhase Labs, Inc. is a listed company in the Pharmaceutical industry, based in New York, New York, USA. It was founded in 1989. Its last known market value was $87 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $4 M and a net loss of $15 M. It employs about 19 people. Its largest business segments by sales in 2025 were Consumer products (100%). Its shares trade under the symbol PRPH (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About ProPhase Labs, Inc.

We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.

Our wholly owned subsidiary, ProPhase BioPharma, Inc. is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand.

Previously we offered a broad array of COVID-19 related clinical diagnostic and testing services including polymerase chain reaction testing for COVID-19 and Influenza A and B as well as rapid antigen testing for COVID-19 through our wholly-owned subsidiary, ProPhase Diagnostics, Inc.. ProPhase Diagnostics’ two CLIA (Clinical Laboratory Improvement Amendments) certified laboratories are located in Old Bridge, New Jersey and Garden City, New York, respectively.

From the company's annual report filed with the US SEC: read the report

ProPhase Labs, Inc. timeline

7 events, 1989–2024
  1. 1989
  2. 🏁
    · approximate
    Founded
  3. 1995
  4. 🔔
    · approximate
    Initial public offering on Nasdaq as PRPH
  5. 1996
  6. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  7. 2010
  8. ✎
    Renamed ProPhase Labs, Inc.
    Formerly Quigley Corp.
  9. 2021
  10. ⊕
    · approximate
    Nebula Genomics became a subsidiary
  11. 2022
  12. 💰
    Record revenue of $123 million
    FY2022, the highest of the 8 years on record.
  13. 2024
  14. ⊕
    · approximate
    DNA Complete became a subsidiary

Events of ProPhase Labs, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$42 M$84 M$126 M$168 M20202021202220232024

World rank over time

▲ up 2,556 places since 2020
2020-01-01: #24708#24,70820202021-01-01: #17936#17,93620212022-01-07: #22116#22,11620222022-12-25: #19351#19,35120222023-07-30: #20520#20,52020232024-01-05: #22152#22,1522024

Rank in USA: #4,451 (Jan 2020) · #3,650 (Jan 2021) · #4,280 (Jan 2022) · #3,910 (Dec 2022) · #4,019 (Jul 2023) · #3,793 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-585.2%
Operating margin
-415.9%
Return on equity
-640.2%
Liabilities / assets
94.1%
Net debt
$1M
Payout ratio
75.0%
Revenue growth
-35.9%
R&D / revenue
2.5%
Revenue per employee
$228 K
Profit per employee
$-776 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $13M, net income $-2M$13MFY18Fiscal year ending Dec 2019: revenue $10M, net income $-3M$10MFY19Fiscal year ending Dec 2020: revenue $15M, net income $-2M$15MFY20Fiscal year ending Dec 2021: revenue $79M, net income $6M$79MFY21Fiscal year ending Dec 2022: revenue $123M, net income $18M$123MFY22Fiscal year ending Dec 2023: revenue $35M, net income $-17M$35MFY23Fiscal year ending Dec 2024: revenue $7M, net income $-53M$7MFY24Fiscal year ending Dec 2025: revenue $4M, net income $-15M$4MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$4M-35.9%$-18M$-15M-339.6%
Dec 2024$7M-80.6%$-39M$-53M-788.2%
Dec 2023$35M-71.5%$-21M$-17M-48.0%
Dec 2022$123M+55.2%$24M$18M15.1%
Dec 2021$79M+444.7%$10M$6M7.9%
Dec 2020$15M+46.9%$-2M$-2M-14.6%
Dec 2019$10M-24.8%$-3M$-3M-31.9%
Dec 2018$13M—$-2M$-2M-13.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-8M$0M$-8M$-1.74—
Dec 2024$-18M$1M$-18M$-26.68—
Dec 2023$-12M$2M$-14M$-0.98—
Dec 2022$29M$4M$25M$1.02—
Dec 2021$-14M$4M$-18M$0.40$0.30
Dec 2020$-3M$2M$-4M$-0.18$0.00
Dec 2019$-1M$0M$-1M$-0.27—
Dec 2018$-2M$0M$-2M$-0.15—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$4M
Net income, trailing 12 months
$-22M
RevenueNet income
Three months to Sep 2024: revenue $1M, net income $-7M$1MSep ’24Three months to Dec 2024 (from the annual report): revenue $1M, net income $-34M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $4M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-4M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-7M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-7M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-5M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-3M$1MJun ’26

Latest quarter to Jun 2026: revenue $1M (-19.2% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of ProPhase Labs, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$4 M
Operating income
$-18 M
Net income
$-15 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$60 M
Total liabilities
$56 M
Total equity
$4 M

As of December-2025

Insider trading at ProPhase Labs, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
ProPhase Labs, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerGift-50,000——3.43 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerGiftindirect+50,000——150,000Form 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerGift-100,000——3.48 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerOption exercise+500,000$0.600$300 K3.85 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerShares withheld for tax-268,337$8.180$2.2 M3.58 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerOption exercise+600,000$0.600$360 K3.67 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerShares withheld for tax-319,231$9.360$3.0 M3.35 MForm 4
filed Ted William KarkusCEO & CHAIRMAN, Director, 10% ownerOption exercise+600,000$0.600$360 K3.39 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: ProPhase Labs, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
54,835
0.6% of shares · 1 days to cover
Buybacks, Q4 2024
$0M
Q4 2024
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

ProPhase Labs, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2024Q4 2024$0M
Q3 2024Q3 2024$0M
Q2 2024Q2 2024$0M
Q1 2024Q1 2024$0M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$0.5M
Q4 2022Q4 2022$1M
Q3 2022Q3 2022$0.1M
Q2 2022Q2 2022$0M
Q1 2022Q1 2022$1.2M
Q4 2017Q4 2017$4.5M
Q3 2017Q3 2017$9.9M

Trading halts

  • 2025-12-20 00:50 UTC, code T3, resumed 14:00 UTC
  • 2025-12-19 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 42 shares at $0.08
  • : 1 shares at $0.12
  • : 1 shares at $0.18
  • : 1 shares at $0.17
  • : 45 shares at $0.22

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

ProPhase Labs, Inc. scorecard#

Passes 0 of the 15 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-35.9%Revenue down 35.9% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-67.2%-67.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-67.2%-67.2% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-1.74 vs -26.68Diluted EPS -1.74 in fiscal 2025 against -26.68 the year before (report's currency).
    • ✗Net income higher than five years earlier-$15 M-$15 M in fiscal 2025 against -$2 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$15 MNet income -$15 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-415.9%-415.9% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-271.4%-271.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-415.9%-415.9% in fiscal 2025 against 19.2% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.06 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-2.6×Operating income -2.6 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year324.4%Diluted shares up 324.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from ProPhase Labs, Inc.'s statements, beside the median of Pharmaceutical.

ProPhase Labs, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-415.9%1.8%
Net margin-339.6%-1.5%
Return on equity-271.5%-0.9%
Revenue growth, 3 years a year-67.2%2.5%
Revenue growth-35.9%7.3%
Free cash flow margin-192.2%6.0%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 35.9% against the year before.
  • Net loss of $15 million, the 3th loss-making year in a row.
  • Free cash flow was negative: -$8 million.
  • The share count rose 324.4% in the year.

ProPhase Labs, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

ProPhase Labs, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue4.36.835r12379159.9139.94.2r
Cost of revenue3.06.919r52379.97.38.37.93.2r
Gross profit1.4−0.216r71424.62.64.81.91.0r
Research and development0.10.61.4r0.70.50.60.30.40.40.4r
Selling and marketing—————1.31.01.10.71.7r
General and administrative193833r34227.5r4.54.94.82.7r
Operating expenses193837r47328.6r5.96.45.94.8r
Operating income−18−39−21r249.8−2.1r−3.2−1.6−4.0−2.7
Interest and finance income———0.20.60.10.10.2——
Interest expense and finance costs6.93.41.30.81.10.3——0.10.2
Net interest income———————0.20.3−0.2
Provision for credit losses—00.16.2——————
Share of profit of associates−0.20————————
Other non-operating income (expense)−0.2−0.00.00————0.10.2
Income before tax−23−42−22r235.3−2.3−3.1−1.5−3.7−4.0r
Income tax07.2−6.04.4−1.00.0—0.1−1.4r—
Income from continuing operations−23−50−16———————
Income from discontinued operations8.6−3.8−0.4——0.2−0.0−0.243r1.1
Net income attributable to shareholders−15−53−17186.3−2.1−3.1−1.741r−2.9
Earnings per share, basic-1.74-26.68r-0.981.170.41-0.18-0.27-0.152.61r-0.17
Earnings per share, diluted-1.74-26.68r-0.981.020.40-0.18-0.27-0.152.59r-0.17
Shares, weighted average (basic)8.52.0r17161512—1116r17r
Shares, weighted average (diluted)8.52.0r17191812121116r17r
Dividends per share————0.300.00————
Balance sheet
Cash and cash equivalents0.10.71.69.18.46.80.41.63.20.4
Short-term investments03.1r3.18.38.81.60.96.719—
Receivables1.52036r37383.22.03.01.95.8
Inventory0.11.12.3r4.04.63.01.51.91.52.7
Other current assets1.52.62.0r2.41.51.2r0.30.30.50.7
Current assets3.231486161169.91828r9.6
Property, plant and equipment2.07.510r7.35.93.62.32.52.73.2
Right-of-use (leased) assets04.14.64.14.44.7————
Goodwill4.05.25.25.75.70.9————
Other intangible assets7.29.8128.5111.2————
Investments in associates430————————
Total assets606392888931122134r13
Accounts payable—148.6r5.97.03.80.40.40.62.2
Current liabilities53322116166.30.94.21.8r6.8
Long-term debt——2.90——————
Lease liabilities (non-current)03.84.24.34.24.4————
Non-current liabilities3.324227.915150.1———
Total liabilities5656432431211.04.2——
Retained earnings−73−58−5.0122.6−3.6−1.54.521r−20
Shareholders' equity3.57.449645911111732r6.0
Total equity3.57.4————————
Total liabilities and equity606392888931122134r13
Shares outstanding9.03.0r18161512————
Cash-flow statement
Depreciation and amortization4.86.26.1r4.73.20.40.40.40.30.4
Share-based compensation1.93.63.54.03.21.50.70.6r0.10.0
Cash from operating activities−8.3−18−12r29−14−2.6r−0.8−2.1−2.8−0.5
Capital expenditure0−0.9−2.1r−3.9−4.2−1.7−0.2−0.1−0.2−0.7
Acquisitions, net of cash acquired—0−2.90−9.1—————
Cash from investing activities0.92.4−1.4−2.1−20−1.05.51222−0.7
Debt issued—————10————
Debt repaid—————————−0.1
Shares issued3.60r0———————
Shares bought back—0−0.6−2.2−0.9———−16—
Dividends paid——0−9.4−4.5—−5.8−12——
Cash from financing activities6.8145.8−263510.0−5.8−11−16−0.1
Change in cash−0.6−0.9−7.5r0.51.86.4−1.1−1.62.7−1.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What ProPhase Labs, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Consumer products$4 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at ProPhase Labs, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 3 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 2

ProPhase Labs, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementNew debt8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Delisting notice8-K
Bylaws or fiscal year changed8-K/A
Bylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K/A
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Directors and officersMaterial agreementBylaws or fiscal year changedShareholder vote8-K
Agreement ended8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 6, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of ProPhase Labs, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$3 MPrivate placement after listing$2 to $10 million2debt, optionsSEC
Jun 2025$1 MPrivate placement after listingUnder $2 million2debt, optionsSEC
Dec 2015$2 MPrivate placement after listingUnder $2 million2debt, optionsSEC
Mar 2010$3 MNo. 1$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at ProPhase Labs, Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $97 K a year.

Certified, FY2024
1
#1,944 among companies on value.today
Worker positions
1
Median wage offered
$97 K
a year, full-time
Applications filed
1
ProPhase Labs, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Research and Development DirectorBiochemists and Biophysicists1$97 K

Where: Garden City, NY 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ProPhase Labs, Inc.

How ProPhase Labs, Inc. compares in Pharmaceutical

  • Revenue$4 M · higher than 4% of 324
  • Net margin-585.2% · higher than 1% of 313
  • Revenue growth-35.9% · higher than 3% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
ProPhase Labs, Inc.🇺🇸$87 M—-585.2%-35.9%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at ProPhase Labs, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show ProPhase Labs, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about ProPhase Labs, Inc.? Suggest a correction